Madeleine Johnson

The firm is offering molecular diagnostic testing and clinical trial services to bridge knowledge gaps and increase access to personalized care locally.

The new system is targeting the clinical space and aims to assist in translating assays from research-use to in vitro diagnostics.

Called the Nio+, the system enables users to run multiple multiplexed experiments using a single instrument.

The partnership is an example of UK-based ReadyGo's strategy to develop molecular infectious disease assays with partners internationally.

Company officials said the firm expects a 25 percent year-over-year increase in the China business in Q4, while its "business, excluding respiratory, will grow in the high teens for the full year 2023."

The firm plans to stay the course on its long-term company transformation goals despite the imminent departure of its chief financial officer, one of the plan's architects.

The graphene sheet method enables low-noise all-electronic DNA detection through application of an alternating electric current, with potential diagnostic applications.

The firm claims to have developed a technology that enables one-minute nucleic acid detection at room temperature without the need for target amplification.

The test, which detects circulating cell-free DNA in urine samples, may help in reaching World Health Organization elimination goals. 

The firm intends to use new funding to move its platform into the clinical trial stage in the pursuit of an FDA-regulated IVD product.